603087.Ss
The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.
Business. The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.
The company maintains a strong liquidity position, with a current ratio of 6.72, indicating a robust ability to meet short-term obligations. Its cash and equivalents amount to 77.43 million CNY, while its operating cash flow stands at 784.28 million CNY, suggesting a healthy cash-generating business model. The company's price-to-book ratio is 2.76, and its price-to-tangible-book ratio is also 2.76, indicating that the market values the company's equity at a premium relative to its book value.
In terms of profitability, the company's return on equity (ROE) is 9.83%, and its return on assets (ROA) is 9.06%, both of which are strong indicators of efficient use of equity and assets. The company's net income of 1.14 billion CNY and operating income of 1.18 billion CNY further underscore its profitability. These metrics suggest that the company is performing well relative to industry standards, although specific industry medians are not provided in the data.
The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the data. However, the company's total revenue of 4.05 billion CNY indicates a significant market presence. The geographic exposure is not explicitly detailed, but the company's operations are likely centered in China, given the CNY-based financials and the ticker symbol.
The company's growth trajectory is positive, with a mean price target of 77.00 CNY from analysts, which is significantly higher than the current market price of 53.64 CNY. This suggests that analysts have a bullish outlook on the company's future performance. The company's revenue history and future outlook are not explicitly detailed, but the strong profitability and liquidity position support a positive growth narrative.
The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's debt-to-equity ratio is 0.0, indicating that it is not leveraged and does not have significant debt obligations. The absence of dilution risks is further supported by the fact that the number of shares outstanding is the same for both basic and diluted shares.
Recent events, such as analyst estimates and price targets, indicate a strong investor sentiment towards the company. The mean recommendation from analysts is 1.50, which is a strong buy rating. The company has received one strong-buy and one buy recommendation, with no hold or sell recommendations, further reinforcing the positive outlook.
- The company has a strong liquidity position with a current ratio of 6.72 and a healthy operating cash flow of 784.28 million CNY.
- The company's profitability is robust, with a return on equity of 9.83% and a return on assets of 9.06%.
- Analysts have a bullish outlook on the company, with a mean price target of 77.00 CNY, significantly higher than the current market price.
- The company has low liquidity and dilution risks, with no immediate filing-based flags detected.
- The company is not leveraged, as indicated by a debt-to-equity ratio of 0.0.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 2,40 |
| Revenue | —no estimate | —no estimate | 4,7B CNY |
| Operating income | —no estimate | —no estimate | 1,4B CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 603087.SS Market data — financials · 2026-05-27
- Gan & Lee Pharmaceuticals Market data — analyst estimates · 2026-05-27